[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR047439A1 - Antagonistas del receptor hidroisoindolina taquiquinina - Google Patents

Antagonistas del receptor hidroisoindolina taquiquinina

Info

Publication number
AR047439A1
AR047439A1 ARP050100203A ARP050100203A AR047439A1 AR 047439 A1 AR047439 A1 AR 047439A1 AR P050100203 A ARP050100203 A AR P050100203A AR P050100203 A ARP050100203 A AR P050100203A AR 047439 A1 AR047439 A1 AR 047439A1
Authority
AR
Argentina
Prior art keywords
hydroisoindoline
taquiquinine
compounds
antagonists
receiver antagonists
Prior art date
Application number
ARP050100203A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR047439A1 publication Critical patent/AR047439A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

El presente se dirige a ciertos compuestos hidroisoindolina los cuales son utiles como antagonistas del receptor de la neuroquinina-1 (NK-1), e inhibidores de taquiquinina y en particular de la sustancia P. el presente también se refiere a formulaciones farmacéuticas que comprenden estos compuestos como ingredientes activos y el uso de los compuestos y sus formulaciones en el tratamiento de ciertos trastornos, incluyendo émesis, incontinencia urinaria, depresion, y ansiedad.
ARP050100203A 2004-01-27 2005-01-20 Antagonistas del receptor hidroisoindolina taquiquinina AR047439A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53991304P 2004-01-27 2004-01-27
US56122704P 2004-04-09 2004-04-09

Publications (1)

Publication Number Publication Date
AR047439A1 true AR047439A1 (es) 2006-01-18

Family

ID=34830494

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100203A AR047439A1 (es) 2004-01-27 2005-01-20 Antagonistas del receptor hidroisoindolina taquiquinina

Country Status (31)

Country Link
US (3) US7645790B2 (es)
EP (1) EP1711465B1 (es)
JP (1) JP3987100B2 (es)
KR (1) KR20060127927A (es)
AR (1) AR047439A1 (es)
AT (1) ATE382034T1 (es)
AU (1) AU2005207934B2 (es)
BR (1) BRPI0507050A (es)
CA (1) CA2554550C (es)
CO (1) CO5700771A2 (es)
CR (1) CR8522A (es)
CY (1) CY1107167T1 (es)
DE (1) DE602005004011T2 (es)
DK (1) DK1711465T3 (es)
EA (1) EA010598B1 (es)
EC (1) ECSP066716A (es)
ES (1) ES2297687T3 (es)
GE (1) GEP20094691B (es)
HK (1) HK1100937A1 (es)
HR (1) HRP20080100T3 (es)
IL (1) IL176879A0 (es)
MA (1) MA28359A1 (es)
NI (1) NI200600164A (es)
NO (1) NO339041B1 (es)
NZ (1) NZ548415A (es)
PE (1) PE20050687A1 (es)
PL (1) PL1711465T3 (es)
PT (1) PT1711465E (es)
TW (1) TWI341198B (es)
UA (1) UA84192C2 (es)
WO (1) WO2005073191A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047439A1 (es) * 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
CA2590039A1 (en) 2004-12-14 2006-06-22 Merck & Co., Inc. Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists
EP1898905A4 (en) * 2005-06-27 2010-06-23 Merck Sharp & Dohme ANTAGONISTS OF TACHYKININ HYDRO-ISO-INDOLIC RECEPTORS
EP1904445B1 (en) * 2005-07-11 2011-03-02 Merck Sharp & Dohme Corp. Process for making hydroisoindoline tachykinin receptor antagonists
ATE511842T1 (de) * 2005-10-04 2011-06-15 Merck Sharp & Dohme Kombinationstherapie zur behandlung von erhöhter miktionsfrequenz, akutem harndrang und inkontinenz
EP1965794A4 (en) * 2005-12-22 2009-10-21 Merck & Co Inc OCTAHYDROPYRANO [3,4-c] pyrrole tachykinin receptor Antagonist
WO2007087224A2 (en) * 2006-01-24 2007-08-02 Merck & Co., Inc. Hexahydro-3h-pyrrolizin-3-ones useful as tachykinin receptor antagonists
CA2662435A1 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
EP2089019A4 (en) * 2006-11-02 2011-05-04 Merck Sharp & Dohme POLYMORPHS OF AN ANTAGONIST OF TACHYKININ HYDRO-ISO-INDOLIC RECEPTORS
US20100113469A1 (en) * 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
AU2008236639B2 (en) * 2007-04-10 2014-07-03 Merck Sharp & Dohme Corp. Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US9782397B2 (en) 2011-07-04 2017-10-10 Irbm Science Park S.P.A. Treatment of corneal neovascularization
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
RU2666219C2 (ru) * 2013-06-24 2018-09-06 Менло Терапьютикс Инк. Применение антагониста рецептора NK-1 серлопитанта при зуде
IL269875B2 (en) 2017-04-10 2024-06-01 Chase Therapeutics Corp NK1 antagonist combination and a method for the treatment of synucleinopathies
MA49524A (fr) 2017-06-30 2021-05-26 Chase Therapeutics Corp Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
JP2021514976A (ja) 2018-02-26 2021-06-17 オスペダーレ・サン・ラッファエーレ・エッセエッレエッレ 眼痛の治療における使用のためのｎｋ−１拮抗薬
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
BR112022018876A2 (pt) 2020-04-03 2022-11-22 Nerre Therapeutics Ltd Antagonista de receptor de nk-1 para tratar uma doença selecionada a partir de sepse, choque séptico, síndrome de desconforto respiratório agudo (ards) ou síndrome de disfunção múltipla dos órgãos
AU2021285503A1 (en) 2020-06-02 2022-12-08 Nerre Therapeutics Limited Neurokinin (NK)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650142A (en) * 1995-09-27 1997-07-22 Church & Dwight Co., Inc. Bicarbonate-containing deodorant cosmetic stick compositions
WO1997014671A1 (en) * 1995-10-18 1997-04-24 Merck & Co., Inc. Cyclopentyl tachykinin receptor antagonists
EP1670476A4 (en) 2003-09-30 2009-05-27 Merck & Co Inc ANTAGONISTS OF TACHYKININ RECEPTOR BASED ON PHENYL PYRROLIDINE ETHER
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina

Also Published As

Publication number Publication date
CR8522A (es) 2007-06-06
JP3987100B2 (ja) 2007-10-03
TW200534850A (en) 2005-11-01
JP2007519728A (ja) 2007-07-19
US20080280966A1 (en) 2008-11-13
US7217731B2 (en) 2007-05-15
EA010598B1 (ru) 2008-10-30
EA200601378A1 (ru) 2007-02-27
ATE382034T1 (de) 2008-01-15
DK1711465T3 (da) 2008-03-31
CY1107167T1 (el) 2012-10-24
US20070161695A1 (en) 2007-07-12
US20050165083A1 (en) 2005-07-28
CO5700771A2 (es) 2006-11-30
IL176879A0 (en) 2006-10-31
NO339041B1 (no) 2016-11-07
AU2005207934A1 (en) 2005-08-11
NO20063810L (no) 2006-10-26
DE602005004011D1 (de) 2008-02-07
PT1711465E (pt) 2008-02-25
NZ548415A (en) 2009-11-27
EP1711465A1 (en) 2006-10-18
TWI341198B (en) 2011-05-01
DE602005004011T2 (de) 2008-12-11
MA28359A1 (fr) 2006-12-01
AU2005207934B2 (en) 2010-11-25
NI200600164A (es) 2007-05-29
GEP20094691B (en) 2009-05-25
CA2554550C (en) 2011-05-03
HK1100937A1 (en) 2007-10-05
US7645790B2 (en) 2010-01-12
WO2005073191A1 (en) 2005-08-11
HRP20080100T3 (en) 2008-04-30
ES2297687T3 (es) 2008-05-01
UA84192C2 (en) 2008-09-25
EP1711465B1 (en) 2007-12-26
PL1711465T3 (pl) 2008-05-30
ECSP066716A (es) 2006-10-31
BRPI0507050A (pt) 2007-06-12
CA2554550A1 (en) 2005-08-11
KR20060127927A (ko) 2006-12-13
US7345083B2 (en) 2008-03-18
PE20050687A1 (es) 2005-09-27

Similar Documents

Publication Publication Date Title
NI200600164A (es) Antagonistas del receptor hidroisoindolina taquiquinina
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
AR055123A1 (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta, composicion farmaceutica que la contiene y su aplicacin en terapeutica
PA8638701A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
PA8638801A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
UY28760A1 (es) Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotrópico
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
UY28150A1 (es) Agentes terapeuticos
UY27095A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para gaba
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
UY26662A1 (es) Compuestos que contienen benzamido-piperidina y compuestos relacionados.
SV2006002098A (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
ECSP066474A (es) Arilindenopiridinas y arilindenopirimidinas y su uso como antagonista del receptor adenosina a2a
ECSP099573A (es) Derivados heterocíclicos como receptores muscarínicos m3
WO2005032464A3 (en) Phenyl pyrrolidine ether tachykinin receptor antagonists
WO2007002457A3 (en) Hydroisoindoline tachykinin receptor antagonists
AR030788A1 (es) Antagonistas de receptores de taquiquinina zwitterionica
WO2007081897A3 (en) Fused triazole tachykinin receptor antagonists
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
AR121183A1 (es) Métodos de tratamiento de la nefritis lúpica con antagonistas de interleucina-17 (il-17)
WO2007075528A3 (en) Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists
WO2006065711A3 (en) Octahydropyrano[3,4-c]pyrrole tachykinin receptor antagonists

Legal Events

Date Code Title Description
FG Grant, registration